Zydus Cadila’s Covid vaccine, ZyCoV-D, is likely to get emergency use authorisation from the Centre this week, as per sources report.
The Covid vaccine candidate of Zydus Cadila is likely to get emergency use authorisation (EUA) from the Centre this week, sources told India Today.
Zydus Cadila applied for the EUA status for its Covid vaccine ZyCoV-D on July 1. The company has conducted the largest clinical trial for its Covid-19 vaccine in India, including on the adolescent population in the 12-18 years age group.
If approved, ZyCoV-D would be the first vaccine in India for the 12-18 years age group.
ZyCoV-D is a three-dose, intradermal vaccine, which is applied using a needle-free system, Tropis, which can also lead to a significant reduction in any kind of side effects.
Currently, the Indian government has authorised five vaccines for Covid-19 which include, Covishield, Covaxin, Sputnik V, Moderna’s vaccine, and J&J’s single-dose vaccine.